Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 868.95 INR
Change Today -27.45 / -3.06%
Volume 910.0K
GNP On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:05 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Open
900.10
Previous Close
896.40
Day High
909.00
Day Low
862.00
52 Week High
04/15/15 - 940.75
52 Week Low
05/19/14 - 507.10
Market Cap
235.7B
Average Volume 10 Days
1.7M
EPS TTM
20.01
Shares Outstanding
271.3M
EX-Date
07/10/14
P/E TM
43.4x
Dividend
2.00
Dividend Yield
0.23%
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GNP)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark Pharmaceuticals Ltd., Board Meeting, Apr 17, 2015

Glenmark Pharmaceuticals Ltd., Board Meeting, Apr 17, 2015. Agenda: To decide to raise funds by way of issue of upto 10,800,000 equity shares of INR 1 each for cash to Aranda Investments (Mauritius) Pte Ltd.; and to decide to convene an extraordinary general meeting of the company.

Glenmark Pharmaceuticals Ltd. Wins Multiple Awardees Contract

Glenmark Pharmaceuticals Ltd. won a multiple awardees contract award from the Secretary of State of Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic transition pharmaceuticals (Contract Award Notice No.: 2015/S 051-088560). The lowest offer is £6.5 million and the higher offer is £7 million.

Glenmark Receives Approval for Generic Seretide in Russia

Glenmark Pharmaceuticals Ltd. announced that it has received approval for Salmecort (Salmeterol+Fluticasone) MDI inhaler, from the Ministry of Health (MoH), Russia. The combination preparation contains salmeterol xinafoate and fluticasone propionate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). The approval is for 25mcg+50mcg/dose, 25 mcg + 125 mcg/dose and 25 mcg + 250 mcg/dose formulation strengths. The approval marks Glenmark's entry into the respiratory inhaler market in Russia. According to IMS, the total inhaler market in Russia is estimated to be around USD 283 million, out of which the total MDI market is valued at around USD 107 million. Salmecort is expected to be available in the Russian market in second Quarter of Fiscal Year 2015-16. In addition to generic Seretide, Glenmark has also received a couple of other key product approvals such as Oflomil nail lacquer, which is the first generic of Loceryl in the Russian market and Sertamycol (sertaconazole) cream in Fiscal Year 2014-15. The company also launched Kerawort (topical imiquimod, generic of Aldara) in the Russian market in Fiscal Year 2014-15.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 868.95 INR -27.45

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,702 INR -65.70
Impax Laboratories Inc $46.66 USD -2.89
Jubilant Life Sciences Ltd 146.00 INR -5.50
Lannett Co Inc $61.90 USD -5.50
View Industry Companies
 

Industry Analysis

GNP

Industry Average

Valuation GNP Industry Range
Price/Earnings 47.6x
Price/Sales 3.7x
Price/Book 7.7x
Price/Cash Flow 31.7x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.